The use of selective inhibitors (including the clinically approved anti-diabetic drug epalrestat) to inhibit AKR1B1 can restore the sensitivity of drug-resistant cell lines to EGFR-TKIs and delay drug resistance in mice harboring xenografted tumors derived from lung cancer patients [202]. This evidence concerns the gene EGFR and lung cancer.